Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Neil F. Mcfarlane is President and CEO at Zevra Therapeutics. OQRO lists 5 transactions filed with the SEC under this name, the latest on Oct 13, 2026, each linked to the official Form 4.
President and CEO
Disclosures on record
5
Companies involved
1
Neil F. Mcfarlane has no open-market purchase on record since 2017 across 2 companies. Sales in 5 of the 10 years since 2017.
Neil F. Mcfarlane reported 0 open-market purchases and 10 sales since 2017; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $225K1×1 trade |
| 2025 | — | $727K2×2 trades |
| 2019 | — | $36K2×2 trades |
| 2018 | — | $486K4×4 trades |
| 2017 | — | $31K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Zevra TherapeuticsZVRA
5 disclosures · Feb 2025 – Oct 2026 · 3 sold
Oct 12, 2026Sold~$225Kdisclosed Oct 13
DetailsOfficial recordOct 10, 202650Kdisclosed Oct 13
DetailsOfficial recordOct 10, 202650Kdisclosed Oct 13
DetailsOfficial recordFeb 13, 2025Sold~$481Kdisclosed Feb 14
DetailsOfficial recordFeb 14, 2025Sold~$246K
DetailsOfficial recordNeil F. Mcfarlane reported 0 open-market purchases and 7 sales here, 2017 to 2019.
Neil F. Mcfarlane reported 0 open-market purchases and 3 sales here, 2025 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
As of the latest filing on , Neil F. Mcfarlane reported holding 417,225 shares of Zevra Therapeutics (ZVRA), worth about $3.92M at the last close of $9 (Nov 17, 2026). In the last 12 months, Neil F. Mcfarlane sold $225K in 1 sale.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Zevra Therapeutics ZVRA | 417,225 | 417K direct | $9 | $3.92M | Oct 12, 2026 |
Is this Neil F. Mcfarlane’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Oct 12, 2026, Neil F. Mcfarlane reported holding 417,225 shares of Zevra Therapeutics (ZVRA). At the last close of $9 on Nov 17, 2026, that is about $3.92M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Neil F. Mcfarlane reported 1 open-market sale worth $225K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Neil F. Mcfarlane has no open-market purchase on record since 2017 across 2 companies. Sales in 5 of the 10 years since 2017.
In SEC filings since 2017: no open-market purchase is on record; the latest open-market sale is from 2026.
2 companies: Zevra Therapeutics (ZVRA, 2025–2026), Travere Therapeutics (TVTX, 2017–2019).